Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study.
Phase of Trial: Phase I/II
Latest Information Update: 21 Feb 2017
At a glance
- Drugs Lenalidomide; Melphalan
- Indications Multiple myeloma
- Focus Adverse reactions
- 13 Feb 2017 Planned End Date changed from 1 Dec 2013 to 1 Dec 2025.
- 13 Feb 2017 Planned primary completion date changed from 1 Dec 2013 to 1 Dec 2022.
- 05 Mar 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.